Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.52 per share, beating the Zacks Consensus Estimate of $4.24 per share. This compares to a loss of $12.83 per share a year ago.
How Will VRTX Stock React To Its Upcoming Earnings?
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements.
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Vertex Pharmaceuticals (VRTX) reached $452.16 at the closing of the latest trading day, reflecting a +1.56% change compared to its last close.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Diabetes Association (ADA) 85th Scientific Sessions Conference Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET Company Participants James Markmann - Corporate Participant Michael Rickels - Corporate Participant Felicia Pagliuca - Corporate Participant Susie Lisa - Senior Vice President of Investor Relations Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Bryan Russell Dollinger - Leerink Partners LLC, Research Division Dina Elmonshed - Jefferies LLC, Research Division Jarwei Fang - Unidentified Company Liisa Ann Bayko - Evercore ISI Institutional Equities, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Mohit Bansal - Wells Fargo Securities, LLC, Research Division Terence C. Flynn - Morgan Stanley, Research Division a division of S&P - Unidentified Company Susie Lisa Thanks for your patience.
